Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02231957

Enrollment

416

Registered

2014-09-04

Start date

2014-07-31

Completion date

2017-01-31

Last updated

2017-01-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vaccination

Brief summary

There are a growing number of adolescents with chronic medical conditions in the United States. The Advisory Committee on Immunization Practices (ACIP) recommends HPV vaccination and annual influenza vaccination of all adolescents. Pneumococcal polysaccharide vaccination is also recommended for certain high-risk patients. Limited studies suggest that vaccination coverage of this population remains sub-optimal. Text message vaccine reminder/recall has been shown to be effective in increasing uptake of select pediatric and adolescents vaccines, but has yet to be examined among patients with chronic medical conditions who may also face unique barriers to vaccination. This intervention aims to implement and evaluate the use of text message vaccine reminders among urban low-income minority adolescents with chronic medical conditions. This investigator-initiated study is supported in part by a grant from the Pfizer Medical Education Group.

Interventions

OTHEReducational text message reminders

OTHERconventional text message reminders

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

TRIPLE (Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

11 Years to No maximum

Healthy volunteers

Inclusion criteria

Parent with 1. adolescent aged 11-17 years; 2. adolescent with ≥1 chronic medical condition; 3. adolescent with clinic visit in last 12 months; 4. cell phone number listed in hospital registration system

Exclusion criteria

Parent who: 1. does not speak English or Spanish; 2. is unwilling to receive text message vaccine reminders; 3. anticipates moving from area in coming 12 months

Design outcomes

Primary

Measure	Time frame
Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)	12 weeks after intervention start

Secondary

Measure	Time frame
Percentage of eligible subjects who received HPV1, influenza, and/or pneumococcal vaccine(s)	4 weeks after intervention start
Percentage of eligible subjects with missed opportunities for HPV1, influenza, and/or pneumococcal vaccination	4 weeks after intervention start

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026